BioMerieux SA
BIM: XPAR (FRA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| &&! | LOCK|@Q&?$ | LOCK|N&@JXF |
BioMérieux Earnings: Strong First-Quarter 2025 Results and Confirmation on Full-Year Guidance
BioMérieux reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales increased in constant currency by 12.7%. Shares are trading 6% lower intraday on April 17.
